Vestibulotoxicity in consequence of tobramycin therapy in cystic fibrosis patients

Vestibulotoxicity in consequence of tobramycin therapy in cystic fibrosis patients - vestibulotoxicity in cystic fibrosis patients

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON29992

Enrollment

Registered

2006-10-30

Start date

2006-11-01

Completion date

Unknown

Last updated

2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

damage of the inner ear disturbance of equilibrium

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: cystic fibrosis patients currently known in the HAGA hospital who have been treated at least one time with intravenous tobramycin and with an audiogram in medical dossier

Exclusion criteria

Exclusion criteria: patients treated with other intravenous aminoglycoside therapy than tobramycine patients receiving intravenous aminoglycosides during investigation. patients with perforation of one of the tympanic membranes. patients with a radical cave.

Design outcomes

Primary

Measure	Time frame
Primary study parameter is formulated as whether there is damage to the vestibulum or there is not.	—

Secondary

Measure	Time frame
Secundary study parameter is formulated as whether there is disturbance of equilibrium due to damage of the vestibulum or there is not.	—

Countries

Netherlands

Outcome results